Use access key #2 to skip to page content.
  • S&P 500: 1,069.30
  • Change: 0.25%
$2.19 -0.03 (-1.35%)
11/6/2009 4:00 PM

Keryx Biopharmaceuticals (KERX)

CAPS Rating:
***

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating KERX

Add Stock to Watchlist

What the Community Thinks

Total Members

118 Outperforms
10 Underperforms
 

All-Stars

27 Outperforms
6 Underperforms
 

Wall Street

2 Outperforms
1 Underperforms
 

Members bullish on KERX are also bullish on:

Members bearish on KERX are also bearish on:

Ticker Tags

Healthcare (737), Defensive (1498), Biotechnology (225), Micro Cap (4871), Growth (1896), Rule Breakers Universe (129)
Suggest a tag

Keryx Biopharmaceuticals At A Glance

Current Price: $2.19
Last Trade Time: 11/6/2009 4:00 PM
Open: $2.25
Previous Close: $2.22
Daily Range: $2.12 - $2.25
52-Week Range: $0.09 - $3.33
Volume: 515,719
Market Cap: $104.77M
P/E Ratio: 24.67
Compare Our Special Broker Offers!

Stock Trends

KERX VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Keryx Biopharmaceuticals (KERX)

Avatar spadesnet (< 20) Submitted: 9/23/09 11:39 PM

This Company is on its way up. They produce life saving and life improving treatments and are the real deal when it comes to bringing them to market. Having recently lost a family member to cancer, and knowing what it is like to wish one of these pharm companies would actually bring to market someth...More

Replies: 1 | Reply | Permalink

Top Bear Pitch

Recs

1

Keryx Biopharmaceuticals (KERX)

Avatar supez2004 (79.75) Submitted: 3/03/08 1:13 AM

Phase 3 for sulodexide unlikely to impress ...

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 24 :   1 2 3 4 5 Next »

Recs

0

 (KERX)

Avatar sOulbAitIsAFool (< 20) Submitted: 10/18/09 7:47 PM : Outperform Start Price: $2.22 KERX Score: 0.43

If you have a few extra coins, this is the one.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (KERX)

Avatar carsondyle (26.59) Submitted: 10/13/09 11:30 AM : Outperform Start Price: $2.56 KERX Score: -16.60

Speculative buy, also really like the potential I see in SNGX.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (KERX)

Avatar rachisme73 (< 20) Submitted: 10/09/09 1:36 PM : Outperform Start Price: $2.19 KERX Score: -0.22

Solid history until 2008, 2 new drugs in phase III trials with promise.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (KERX)

Avatar kingleader (50.26) Submitted: 10/07/09 11:52 AM : Outperform Start Price: $2.12 KERX Score: 1.64

With promising trials underway the stock should move up on any good news.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (KERX)

Avatar mmerinpa (< 20) Submitted: 9/27/09 4:28 AM : Outperform Start Price: $2.62 KERX Score: -18.59

it has two good drugs in phase 3 trials and just got approval in UK for one of them, a new class of drugs to treat multiple myeloma.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 24 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 3 of 3  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackBearStearns 86.38 09/17/09 Underperform NS $1.88+16.49%+1.45%-15.04
TrackPZK < 20 09/16/09 Outperform NS $1.88+16.49%+1.45%+15.04
TrackBreanMurray 89.84 09/16/09 Outperform NS $1.88+16.49%+1.45%+15.04

Results 1 - 3 of 3  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 656ms